Sign in
CompletedPhase 2

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Key facts

Who runs it
University of Minnesota
Where
Uganda2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
48 people enrolled
Started
9 Apr 2024
Ended
2 Oct 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • AMBITION trial control
  • Flucytosine
Record updated
27 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • CSF cryptococcal antigen (CrAg) positive meningitis
  • Ability and willingness to provide informed consent
  • Willing to receive protocol-specified lumbar punctures

Who cannot take part

  • Receiving chemotherapy or corticosteroids
  • Patients with prior 5-flucytosine exposure >3 days in the 12 months prior to enrollment
  • Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)
  • Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments
  • Absolute neutrophil count <500 x10 6 cells/L
  • Age <18 years
  • Inability to take enteral (oral or nasogastric) medicine
  • Cannot or unlikely to attend regular clinic visits
  • Pregnancy or breastfeeding
  • CrCl < 20 mL/minute
  • Thrombocytopenia < 50,000 x 10 6 cells/L

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cryptococcal meningitis (CM) is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in Africa where the ongoing HIV/AIDS pandemic leads to higher prevalence of cryptococcosis. Combination of amphotericin and flucytosine (5-FC) is the mainstay of therapy for the initial management of CM. Indeed, it has even been shown that effective delivery of these therapies in Africa can lower mortality rates by 90%.

Read full original descriptionShow less

This is a prospective open-label trial to compare the efficacy and safety of lower doses of 5FC during induction therapy to historical controls with standard 5FC dosing. Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed. Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received. Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days. The intervention group received single- dose liposomal amphotericin plus 5-FC and fluconazole 1200 mg/day.

All participants will receive fluconazole 1200mg/day during consolidation therapy from day 1 to 14 then 800mg/day from day 15 to 10 weeks, and 200mg/day after 10 weeks. All participants will receive lumbar punctures at diagnosis, day 3, day 5-7, day 10-14, and additionally as required for control of intracranial pressure and documentation of CSF sterilization. Controls from Ambition will be matched for the same LP windows. Therapeutic LPs conducted during the first week have a ~70% relative survival benefit.

The 2 groups in the trial

  • controlExisting treatment, for comparison

    Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received.

    Treatment: AMBITION trial control

  • Low Dose FlucytosineTreatment being tested

    HIV-infected persons in Uganda with cryptococcal meningitis

    Treatment: Flucytosine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
27 August 2025